These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1475804)

  • 1. Aspects of tuberculosis in Africa. 1. Tuberculosis in Africa in the AIDS era--the role of chemoprophylaxis.
    Porter JD; McAdam KP
    Trans R Soc Trop Med Hyg; 1992; 86(5):467-9. PubMed ID: 1475804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprophylaxis for tuberculosis in HIV-infected individuals in sub-Saharan Africa.
    Nuwaha F
    East Afr Med J; 1998 Sep; 75(9):520-7. PubMed ID: 10493054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
    Halsey NA; Coberly JS; Desormeaux J; Losikoff P; Atkinson J; Moulton LH; Contave M; Johnson M; Davis H; Geiter L; Johnson E; Huebner R; Boulos R; Chaisson RE
    Lancet; 1998 Mar; 351(9105):786-92. PubMed ID: 9519950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world.
    Sterling TR; Brehm WT; Moore RD; Chaisson RE
    Int J Tuberc Lung Dis; 1999 Mar; 3(3):248-54. PubMed ID: 10094327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients--a least-cost analysis.
    Masobe P; Lee T; Price M
    S Afr Med J; 1995 Feb; 85(2):75-81. PubMed ID: 7597538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of the HIV epidemic on tuberculosis control programmes in developing countries.
    Veeken H; Bermejo A
    Trop Doct; 1992 Apr; 22(2):64-7. PubMed ID: 1344023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
    Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA
    AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients.
    Casado JL; Moreno S; Fortún J; Antela A; Quereda C; Navas E; Moreno A; Dronda F
    Clin Infect Dis; 2002 Feb; 34(3):386-9. PubMed ID: 11753825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease.
    Mohammed A; Myer L; Ehrlich R; Wood R; Cilliers F; Maartens G
    Int J Tuberc Lung Dis; 2007 Oct; 11(10):1114-20. PubMed ID: 17945069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Indications for chemoprophylaxis of tuberculosis. Arguments for].
    Nicod LP
    Schweiz Med Wochenschr; 1993 Feb; 123(5):154-8. PubMed ID: 8438136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of latent tuberculosis infection in HIV infected persons.
    Woldehanna S; Volmink J
    Cochrane Database Syst Rev; 2004; (1):CD000171. PubMed ID: 14973947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis.
    Gourevitch MN; Alcabes P; Wasserman WC; Arno PS
    Int J Tuberc Lung Dis; 1998 Jul; 2(7):531-40. PubMed ID: 9661818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis in HIV infection.
    Horner PJ; Moss FM
    Int J STD AIDS; 1991; 2(3):162-7. PubMed ID: 1863645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic review: tuberculosis.
    Houston S; Pozniak A; Ray CS
    Cent Afr J Med; 1991 Aug; 37(8):250-9. PubMed ID: 1807799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Human immunodeficiency virus infection and tuberculosis: who should receive chemoprophylaxis?].
    Moreno Guillén S
    Rev Clin Esp; 1994 Feb; 194(2):73-4. PubMed ID: 8008942
    [No Abstract]   [Full Text] [Related]  

  • 18. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world.
    Kaplan JE; Hu DJ; Holmes KK; Jaffe HW; Masur H; De Cock KM
    Am J Trop Med Hyg; 1996 Jul; 55(1):1-11. PubMed ID: 8702012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy.
    Vikrant S; Agarwal SK; Gupta S; Bhowmik D; Tiwari SC; Dash SC; Guleria S; Mehta SN
    Transpl Infect Dis; 2005; 7(3-4):99-108. PubMed ID: 16390397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tuberculosis and the HIV pandemic. Risk of nosocomial tuberculosis infection].
    Pedersen C; Kolmos HJ; Nielsen JO
    Ugeskr Laeger; 1997 Feb; 159(9):1233-8. PubMed ID: 9072866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.